https://www.yiliao.com/index.php?action=history&feed=atom&title=Anetumab_ravtansine
Anetumab ravtansine - 版本历史
2026-04-18T22:28:55Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Anetumab_ravtansine&diff=314238&oldid=prev
223.160.138.80：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-13T08:13:33Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Anetumab ravtansine]]</strong>（研发代码：<strong>[[BAY94-9343]]</strong>）是一种针对<strong>[[间皮素]]</strong>（Mesothelin,<strong>[[MSLN]]</strong>）的创新抗体偶联药物（<strong>[[ADC]]</strong>）。它由全人源抗<strong>[[MSLN]]</strong>单克隆抗体通过可剪切的二硫键接头，与强效微管抑制剂<strong>[[Ravtansine]]</strong>（<strong>[[DM4]]</strong>，一种美登木素衍生物）偶联而成。<strong>[[Anetumab ravtansine]]</strong>旨在通过靶向在<strong>[[恶性间皮瘤]]</strong>、<strong>[[卵巢癌]]</strong>及<strong>[[胰腺癌]]</strong>等实体瘤中高度表达的<strong>[[间皮素]]</strong>，实现细胞毒性载荷的精准递送。目前，该药物正在多项临床研究中评估其作为单药或联合<strong>[[免疫检查点抑制剂]]</strong>治疗晚期实体瘤的潜力，是针对<strong>[[MSLN]]</strong>靶点开发进度最快的<strong>[[ADC]]</strong>药物之一。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Anetumab ravtansine</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">BAY94-9343·间皮素靶向ADC·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 10px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">ADC Structure:Anti-MSLN mAb+DM4</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：<strong>[[MSLN]]</strong>(间皮素)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;"><strong>[[Entrez]]</strong>ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">10232(<strong>[[MSLN]]</strong>)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;"><strong>[[UniProt]]</strong></th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q13421</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">毒性载荷</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[DM4]]</strong>(微管抑制剂)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物抗体比</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">平均DAR约为3.2</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[拜耳]]</strong>(Bayer)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">研究阶段</th><br />
<td style="padding: 12px; color: #f59e0b;">临床II/III期</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">药理机制：MSLN靶向递送与微管阻断</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[Anetumab ravtansine]]</strong>通过模拟“生物导弹”的模式，对高表达间皮素的癌细胞进行定向清除：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">受体识别与结合：ADC的抗体部分（人源化IgG1）高亲和力结合肿瘤表面的<strong>[[间皮素]]</strong>（MSLN）。间皮素在正常组织中表达极低，但在多种侵袭性实体瘤中广泛过表达，提供了良好的治疗窗。</li><br />
<li style="margin-bottom: 12px;">内吞与载荷释放：结合后，<strong>[[ADC]]</strong>复合物通过受体介导的<strong>[[内吞作用]]</strong>进入溶酶体。在溶酶体环境及谷胱甘肽作用下，二硫键接头被切割，释放出活性载荷<strong>[[DM4]]</strong>。</li><br />
<li style="margin-bottom: 12px;">微管抑制与凋亡：释放出的<strong>[[DM4]]</strong>作为强效微管蛋白抑制剂，阻止微管蛋白聚合，使肿瘤细胞周期阻滞于G2/M期，最终诱导细胞<strong>[[凋亡]]</strong>。</li><br />
<li style="margin-bottom: 12px;">旁路杀伤效应：DM4具有一定的脂溶性，能够穿透细胞膜扩散至相邻的<strong>[[MSLN]]</strong>低表达癌细胞，实现对异质性肿瘤的更广泛打击。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价：关键研究数据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床试验</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">目标人群</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键数据结论</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[ARCS-M]] 研究</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">既往治疗失败的<strong>[[恶性胸膜间皮瘤]]</strong>。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">二线单药对比长春瑞滨，中位PFS未达显著差异，但其安全性及亚组获益仍具有探索价值。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[NCT03587311]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>[[MSLN]]</strong>阳性复发性<strong>[[卵巢癌]]</strong>。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">评估联合<strong>[[帕博利珠单抗]]</strong>的安全性，展现了ADC与免疫疗法协同增效的潜力。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">安全性摘要</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;" colspan="2;">主要不良反应为<strong>[[眼部毒性]]</strong>（角膜病变）、转氨酶升高及疲劳。眼部毒性可通过定期监测和药物干预管理。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：检测筛选与毒性精细化管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[Anetumab ravtansine]]</strong>的临床应用体现了对特定生物标志物及其脱靶毒性的精细化掌控：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">受体表达定量：为了筛选获益人群，临床常通过<strong>[[免疫组化]]</strong>（IHC）检测肿瘤组织中<strong>[[MSLN]]</strong>的表达水平，通常以中至高强度表达作为入组基准。</li><br />
<li style="margin-bottom: 12px;">眼科监测方案：鉴于<strong>[[Ravtansine]]</strong>（DM4）载荷具有引起<strong>[[角膜病变]]</strong>的风险，用药期间需强制执行眼科常规检查，并在给药前使用润滑眼药水或预防性局部类固醇。</li><br />
<li style="margin-bottom: 12px;">肝功能监测：部分患者会出现一过性的<strong>[[ALT/AST]]</strong>升高，临床需在每周期给药前进行肝生化指标评估。</li><br />
<li style="margin-bottom: 12px;">未来组合探索：目前的趋势是将该ADC与<strong>[[PD-1]]</strong>抑制剂或抗血管生成药物联用，以期在单药未能突破的<strong>[[间皮瘤]]</strong>二线治疗中寻求更长的<strong>[[mOS]]</strong>。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[间皮素]]</strong>(MSLN)：一种糖基磷脂酰肌醇(GPI)锚定蛋白，是肺膜、腹膜间皮细胞的标志物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Ravtansine]]</strong>(DM4)：强效美登木素类毒素，其抗肿瘤活性通常是常规化疗药物的数百倍。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Mirvetuximab Soravtansine]]</strong>：全球首个获批的FRα靶向ADC，其载荷与Anetumab ravtansine相似，具有重要的临床参考意义。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Bayer]]</strong>：拜耳医疗，全球领先的肿瘤创新药物研发制药企业。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Hassan R, et al. (2020).</strong> <em>Anetumab Ravtansine versus Vinorelbine in Patients with Relapsed Mesothelin-positive Malignant Pleural Mesothelioma (ARCS-M).</em> <strong>[[Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该临床试验确立了MSLN-ADC在复发性间皮瘤中的安全性概况，并引发了对间皮素检测异质性的学术讨论。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Golfier S, et al. (2014).</strong> <em>An Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343 with Potent Antitumor Activity in Mesothelin-Expressing Tumors.</em> <strong>[[Molecular Cancer Therapeutics]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：系统阐述了该药在临床前模型中卓越的选择性杀伤活性及二硫键接头的稳定性优势。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
Anetumab ravtansine(MSLN-ADC)研发生态·知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[MSLN]]</strong>•<strong>[[GPI]]</strong>•<strong>[[Tubulin]]</strong>•<strong>[[PD-1]]</strong>•<strong>[[MUC1]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类管线</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[Mirvetuximab Soravtansine]]</strong>•<strong>[[DMUC5754A]]</strong>•<strong>[[Amatuximab]]</strong>•<strong>[[RC88]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[Bayer]]</strong>•<strong>[[FDA]]</strong>•<strong>[[ImmunoGen]]</strong>•<strong>[[ESMO]]</strong>•<strong>[[ASCO]]</strong></td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿探索</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[一线联合免疫治疗研究]]</strong>•<strong>[[针对MSLN低表达人群探索]]</strong>•<strong>[[眼部毒性预防方案优化]]</strong>•<strong>[[胃腺癌MSLN靶点评估]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.80